SCHEMBL4863308

SCHEMBL4863308

CC(C)c1nc(NCc2cccc(F)c2)c2ccccc2n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 9/20 0.68
CCNE2 O96020 2/20 0.65
CCNE1 P24864 2/20 0.65
CDK2 P24941 2/20 0.65
BCHE P06276 2/20 0.52
ACHE P22303 2/20 0.52
AURKA O14965 1/20 0.51
AURKB Q96GD4 1/20 0.51
RAD52 P43351 1/20 0.50
MAPT P10636 4/20 0.49
LMNA P02545 3/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
PKM P14618 1/20 0.49
UBE2N P61088 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
RCE1 Q9Y256 1/20 0.49
PDE5A O76074 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866463 0.88 LMNA (0.61) APPCCNE2CCNE1CDK2BCHE
SCHEMBL4863048 0.87 APP (0.66) APPBCHEACHERAD52MAPT
SCHEMBL4859931 0.85 APP (0.70) APPCCNE2CCNE1CDK2BCHE
SCHEMBL4863396 0.84 APP (0.73) APPCCNE2CCNE1CDK2BCHE
SCHEMBL4863323 0.83 APP (0.71) APPBCHEACHEMAPTLMNA
SCHEMBL2580376 0.82 RAD52 (0.76) APPCCNE2CCNE1CDK2BCHE
SCHEMBL4888593 0.81 CCNE2 (0.80) APPCCNE2CCNE1CDK2BCHE
SCHEMBL4867531 0.80 MEN1 (0.76) APPCCNE2CCNE1CDK2MAPT
SCHEMBL4861406 0.80 APP (0.71) APPCCNE2CCNE1CDK2BCHE
SCHEMBL4860088 0.79 APP (0.65) APPCCNE2CCNE1CDK2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R APP 4386/4885CCNE2 3496/4885CCNE1 3853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.